AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01851369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5-HT3 antagonist
Description: If a participant develops nausea/vomiting, an anti-emetic such as 5-HT3 antagonist may be given.
Study NCT01851369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: If a participant develops nausea/vomiting, an anti-emetic such as aprepitant may be given.
Study NCT01912118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil will be provided by a target controlled infusion to a specific effect site concentration (as specified in treatment arm)
Study NCT00443651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab was supplied as a concentrate for IV administration at a concentration of 10 mg/mL in 500 mg (50 mL) single-use vials.
Study NCT00443651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory drugs
Description: Each rituximab infusion was preceded by methylprednisolone 100 mg IV. Use of stable doses of oral corticosteroids was permitted (≤ 10 mg of prednisone or equivalent per day) as were stable doses of nonsteroidal anti-inflammatory drugs (NSAIDs).
Study NCT06559904 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mediterranean diet
Description: The 'Mediterranean Diet Education Document', prepared by the researcher, which includes general information about the characteristics of the Mediterranean diet and the portion sizes that should be followed daily and weekly, and information on how often, how much and when to consume food groups, was provided as a diet education, and information was provided on how to record three-day food consumption.~A nutrition education compatible with the Mediterranean diet, organized by the researcher according to the individual's daily needs, was provided and a sample menu was explained to the individual face to face.
Study NCT02875392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 275mg Oligo Fucoidan + 275mg HS Fucoxanthin
Description: Fucoidan is a water-soluble dietary fiber which is extracted from brown seaweed. Slimy surface of brown seaweed has unique ingredients and different kind of brown seaweed has slightly different effectiveness.The subject of this study focus on assessing the impact on the metabolism of fatty liver and liver fibrosis after taking oral FucoHiQ capsules.
Study NCT02875392 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo pills
Description: taking placebo pills as if patients are under treatment.
Study NCT01175135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02545920
Description: 5 mg tablet every 12 hours for 28 days
Study NCT01175135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02545920
Description: 15 mg tablet every 12 hours for 28 days
Study NCT01175135 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet/capsule every 12 hours for 28 days
Study NCT01175135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: 3 mg capsule every 12 hours for 28 days
Study NCT02641444 — intervention group
Intervention type: PROCEDURE
Intervention: Blood plasma collection
Description: Approximately 3mL of blood will be taken from each subject just prior to the colonoscopy.
Study NCT02641444 — intervention group
Intervention type: PROCEDURE
Intervention: Cervical and Vaginal Biopsy
Description: 2 biopsies each will be collected from the vaginal wall and the cervix
Study NCT02641444 — intervention group
Intervention type: PROCEDURE
Intervention: Colonoscopy with Ileal and Rectal Biopsy
Description: 10 biopsies each will be collected from the rectum and terminal ileum from each subject during the colonoscopy.
Study NCT04476511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: tablet containing 30.000IU cholecalciferol
Study NCT00834418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide 20 mg Tablets
Description: 1 x 20 mg, single-dose fasting
Study NCT00834418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARAVA™ 20 mg Tablets
Description: 1 x 20 mg, single-dose fasting
Study NCT01242098 — intervention group
Intervention type: DRUG
Intervention: Fixed dose combination salmeterol / fluticasone
Description: Branded fixed-dose combination inhaled corticosteroid / long-acting beta2-agonist therapy
Study NCT01242098 — intervention group
Intervention type: DRUG
Intervention: Fixed-dose combination beclometasone dipropionate / formoterol
Description: Branded fixed-dose combination inhaled corticosteroid / long-acting beta2-agonist therapy
Study NCT01910038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticoids+ tocilizumab 8mg/Kg/4 weeks
Study NCT05125900 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Proximal box elevation using one of the tested materials
Description: Each patient randomly received deep proximal margin elevation with one of the tested restorative materials, while the overlying restorations were all the same regular bulk fill resin composite
Study NCT05125900 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Proximal box elevation using one of the tested materials
Description: Each patient randomly received deep proximal margin elevation with one of the tested restorative materials, while the overlying restorations were all the same regular bulk fill resin composite
Study NCT02552758 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acid
Description: omega-3 fatty acid
Study NCT02552758 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT02552758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: positron emission tomography (PET)
Study NCT02552758 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: positron emission tomography (PET)
Study NCT02163382 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurovent Monitor XIII
Description: Nasogastric tiube installation to monitor EAdi
Study NCT02163382 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurovent Monitor XIII
Description: RIP jacket installation
Study NCT02163382 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurovent Monitor XIII
Description: Ventilator change (if a different ventilator was used prior to the study).
Study NCT02163382 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurovent Monitor XIII
Description: Determination of NAVA parametersVentilator
Study NCT02163382 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurovent Monitor XIII
Description: Second period with conventional NIV settings
Study NCT00926835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paroxetine
Description: 6 weeks, 20-50mg/day
Study NCT00926835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 10-20mg/day for 6 weeks
Study NCT00926835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine XR
Description: Venlafaxine 75-225mg/day for 6 weeks
Study NCT00926835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine+Bupropion
Description: paroxetine 20-50mg/day + bupropion 150-400mg/day for 6 weeks
Study NCT00926835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine+Lamotrigine
Description: Paroxetine 20-50mg/day + lamotrigine 100-400mg/day for 6 weeks
Study NCT00926835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine+Lithium
Description: Paroxetine 20-50mg/day + lithium 0.5-1.2 mEq/L
Study NCT00926835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram+Mirtazapine
Description: escitalopram 10-20mg/day + mirtazapine 15-45mg/day for 6 weeks
Study NCT00926835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram+Aripiprazole
Description: escitalopram 10-20mg/day + aripiprazole 5-15mg/day for 6 weeks
Study NCT01851369 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Tumor biopsies will be optional during the escalation phase.
Study NCT02966925 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellular Matrix BCT-HA Kit
Description: Submucosal injections in the vulva, in the posterior vaginal wall and in the perineum of a combination product made of PRP and HA prepared using the Cellular Matrix BCT-HA medical device
Study NCT00940459 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Senofilcon A contact lens (Acuvue Oasys)
Description: Silicone hydrogel contact lens CE-marked for the intended usage.
Study NCT00940459 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comfilcon A contact lens (Biofinity)
Description: Silicone hydrogel contact lens CE-marked for the intended usage.
Study NCT00940459 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B contact lens (Air Optix)
Description: Silicone hydrogel contact lens CE-marked for the intended usage.
Study NCT00926835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine + Venlafaxine XR
Description: Paroxetine 20-50mg/day + Venlafaxine 75-225mg/day for 6 weeks
Study NCT00940459 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balafilcon A contact lens (PureVision)
Description: Silicone hydrogel contact lens CE-marked for the intended usage.
Study NCT00940459 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A contact lens (Acuvue 2)
Description: Hydrogel contact lens CE-marked for the intended usage.
Study NCT00940459 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contact lens care system (EasySept)
Description: Contact lens care system CE-marked for the intended usage.
Study NCT00940459 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact lens care system (EasySept)
Description: Contact lens care system CE-marked for the intended usage.
Study NCT00831103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPB-348
Description: Treated over seven days
Study NCT01774448 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy
Description: In the experimental condition, individuals with dementia (n = 15) and their spouses (n = 15) will partake in one MBCT session per week for 8 weeks. The partners will attend separate MBCT sessions (different day of the week). In the control condition, individuals with dementia (n = 15) and their spouses (n= 15) will go through an 8-week waitlist control period.
Study NCT01251523 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PACE
Description: The first intervention to be tested, Physician Asthma Care Education (PACE), is a rigorously evaluated intervention for physicians that has reached hundreds of clinicians across the U.S. and also has been implemented in the United Kingdom and Australia. The efficacy trial of PACE was supported by the National Heart, Lung and Blood Institute and the effectiveness trial by the Robert Wood Johnson Foundation. PACE is now widely available to clinicians, through, among other channels, the National Asthma Education and Prevention Program (NAEPP). It is designed to enhance physician communication, counseling and therapeutics for assisting the general population of children with asthma.
Study NCT01251523 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PACE Plus
Description: In the PACE PLUS intervention a cultural competence component will be added to the PACE curriculum. The cultural competence component uses mini-lecture, video demonstration (video to be developed as part of this proposal), case studies and self observation tools to present the principles of cultural competence derived from the study of the literature. The component integrates into the skills taught, specific content related to working with African American and Puerto Rican families where a child has asthma.
Study NCT00881205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch
Description: Transdermalapplication of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size. All patches are round, beige in color.
Study NCT00881205 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Transdermal application of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size. Matching the size, shape and color of rivastigmine patches.
Study NCT03902990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual task
Description: The patients in the dual task group received cognitive tasks during treadmill training sessions.
Study NCT00550238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin tartrate (ACP-103)
Description: Tablets taken once daily by mouth for as long as ACP-103 is considered to be tolerated and beneficial to subjects
Study NCT00640783 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: The dietary advice was tailored to each patient on the basis of 3-day food records. The recommended composition of the dietary regimen was as follows: carbohydrates, 50% to 60%; proteins, 15% to 20%; total fat, less than 30%; saturated fat, less than 10%; and cholesterol consumption, less than 300 mg per day. Moreover, patients were advised to consume at least 250 to 300 g of fruits, 125 to 150 g of vegetables, and 25 to 50 g of walnuts per day; in addition, they were also encouraged to consume 400 g of whole grains (legumes, rice, maize, and wheat) daily and to increase their consumption of olive oil.
Study NCT00640783 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Patients consuming the control diet were given general oral and written information about healthy food choices at baseline and at subsequent visits but were offered no specific individualized program. However, the general recommendation for macronutrient composition of the diet was similar to that for the intervention group (carbohydrates, 50%-60%; proteins, 15%-20%; and total fat, \<30%).
Study NCT02651181 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HLCL- Hybrid Logic Closed Loop System
Description: All subjects wearing the HLCL System and using it with the closed loop algorithm
Study NCT00849888 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Serum Free Thymus Transplantation with Immunosuppression
Description: Cyclosporine pre-transplant (trough 180-220ng/ml) until naive T cells develop. Subjects >4,000/cumm T cells, pre-transplant methylprednisolone or prednisolone 1-2mg/kg/day. All subjects pre-transplant days -5,-4,-3: 3 doses 2mg/kg rabbit anti-thymocyte globulin. Thymus tissue (unrelated donor), donor, \& donor's mother screened for safety. Transplant under general anesthesia into quadriceps. First 2 subjects, FBS cultured thymus is transplanted in 1 leg \& serum free (SF) in other. After first 2 subjects >10% naïve T cells, 3rd receives only SF thymus. After 3rd subject >10%naive T cells, 4th subject transplanted. Thymus dose 4-18 grams/m2 body surface area. Thymus biopsy 8-12 weeks post-transplant. Skin biopsy at time of transplant \& thymus biopsy. Followed by immune evaluations.
Study NCT00831103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir
Description: Treated over seven days
Study NCT04562935 — intervention group
Intervention type: OTHER
Intervention: admission to pediatric intensive care with mechanical ventilation
Description: admission to pediatric intensive care with mechanical ventilation
Study NCT01904162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg finafloxacin (2 x 200 mg tablets)
Study NCT00849888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serum Free Thymus Transplantation without immunosuppression
Description: Thymus tissue (unrelated donor), donor, \& donor's mother screened for safety. Transplant under general anesthesia into quadriceps. First 2 subjects: FBS cultured thymus transplanted in 1 leg \& serum free cultured thymus in other leg. After first 2 subjects have thymopoiesis in serum-free biopsy, >10% naïve T cells, 3rd subject receives only serum free cultured thymus. After 3rd subject >10% naive T cells, 4th subject receives transplant of only serum free cultured thymus. Dose 4-18grams/m2 body surface area. At time of transplant, skin biopsy. Allograft biopsy \& skin biopsy done 8 to 12 weeks post-transplant. (Graft biopsy not done if subject medically unstable.) Post-transplant, subjects followed by immune evaluations, using blood samples, for two years.
Study NCT02484859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil infusion will be started with a bolus dose of 0.5 µg/kg before the induction, and will be continued throughout the surgery at a dose of 0.25-0.5 µg/kg/min. At the end of the surgery, the rate of infusion will be decreased to 0.05 µg/kg/min, and continued until the patient is extubated.
Study NCT02484859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: 1 mg/kg tramadol will be added to 100 ml of isotonic fluid, and will be administered intravenously in exactly 30 minutes via a perfusor. The infusion will be started just before the induction.
Study NCT02484859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: 0.1 mg/kg of metoprolol will be administered intravenously within 5 minutes following the administration of neuromuscular blocking agent.
Study NCT00991068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synera (lidocaine 70 mg and tetracaine 70 mg) topical patch
Description: Patients will apply a single Synera patch to the target wrist for 2 hours twice a day (ie, morning and evening applications) for 14 days.
Study NCT01680510 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alga Dunaliella Bardawil
Study NCT01680510 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alga Dunaliella Bardawil
Study NCT01680510 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (starch)
Study NCT01680510 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (starch)
Study NCT02320903 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VillageWhere App
Study NCT00730028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Description: Trimethoprim-sulfamethoxazole (TMP-SMX) will be administered orally at a dose of 160 mg TMP and 800 mg SMX (as 2 single strength over encapsulated tablets) twice daily (adult or child > 40 kg dose) or 8-10 mg TMP, 40-50 mg SMX per kg daily, divided into 2 daily doses (child \< 40 kg dose). Study drug will be administered for 10 days.
Study NCT02513381 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3, 3200IU
Description: Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.
Study NCT02513381 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.
Study NCT03502135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracaine HCl and oxymetazoline HCl nasal spray
Description: Two intranasal sprays of anesthetic. Each spray delivers 0.2 mL of solution containing 6 mg tetracaine hydrochloride and 0.1 mg of oxymetazoline hydrochloride
Study NCT04511299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMOFlipid 20%
Description: Fish oil-enriched intravenous lipid emulsion
Study NCT04511299 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lipofundin 20%
Description: MCT/LCT standard intravenous lipid emulsion
Study NCT04071665 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified lateral lumbar interbody fusion
Description: Modified lateral lumbar interbody fusion
Study NCT04071665 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified lateral lumbar interbody fusion
Description: Modified lateral lumbar interbody fusion
Study NCT02627950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphinhydrochloricum
Description: 5 mg morphine intravenously
Study NCT02627950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: 10 mg MCP intravenously
Study NCT02627950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: 180 mg ticagrelor orally
Study NCT02627950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: 180 mg ticagrelor orally
Study NCT02627950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic sodium chloride
Description: 10 ml NaCl 0.9% intravenously
Study NCT04336176 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PulseFlow DF boot
Description: Offloading boot
Study NCT04336176 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PulseFlow DF boot
Description: Offloading boot
Study NCT04336176 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usual standard of care
Description: Usual standard of care (offloading device)
Study NCT04336176 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Usual standard of care
Description: Usual standard of care (offloading device)
Study NCT04336176 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham
Description: Sham shoe (closest to barefoot or baseline pressures)
Study NCT04336176 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham shoe (closest to barefoot or baseline pressures)
Study NCT01936337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DLX105 Hydrogel
Description: topical administration on psoriatic plaque